(Q37739480)

22 August 2017

1 reference

title

Rheumatoid arthritis therapy: advances from bench to bedside (English)

1 reference

22 August 2017

1 reference

Soo-In Choi

1

1 reference

PubMed ID

20429843

22 August 2017

Ernest Brahn

series ordinal

2

1 reference

22 August 2017

1 November 2010

1 reference

22 August 2017

1 reference

22 August 2017

43

1 reference

22 August 2017

7

1 reference

22 August 2017

478-492

1 reference

Epidemiology of adult rheumatoid arthritis

22 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Immunologic mechanisms in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

IL-17 as a future therapeutic target for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Mechanisms of Disease: the link between RANKL and arthritic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Primer: signal transduction in rheumatic disease--a clinician's guide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Tyrosine kinases as targets for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916931003674717

10.3109/08916931003674717

21 January 2018

Identifiers

DOI

1 reference

release_6zlsx2n7xndengkt66sftnjfkm

22 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6zlsx2n7xndengkt66sftnjfkm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

20429843

1 reference

PubMed ID

20429843